MetaCap

CG Oncology Inc. Company Profile

NASDAQ: CGONHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

79.47-2.43 (-2.97%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CG Oncology at a glance

CG Oncology Inc. (NASDAQ: CGON) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Dallas, TX. CG Oncology is led by Mr. Arthur Kuan and employs about 142 people. The company's shares have traded publicly since 2024.

At a market capitalization of $7.10 billion, it is considered a mid-cap company. Its SEC Central Index Key (CIK) is 0001991792, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does CG Oncology do?

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Dallas, Texas.

Business description based on the company's public filings.

Company information

Legal name
CG Oncology Inc.
Ticker
NASDAQ: CGON
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Arthur Kuan
Employees
142
Headquarters
3000 Pegasus Park Drive, Dallas, TX, United States
Phone
949 409 3700
IPO year
2024
SEC CIK
0001991792
Latest annual report
10-K · Feb 27, 2026

Companies similar to CG Oncology

CGON peer companies
CompanyPrice% ChgMarket capCompare
TWSTTwist Bioscience Corporation103.32-7.44%$7.04Bvs CGON
IMVTImmunovant Inc.31.77-2.31%$6.57Bvs CGON
IBRXImmunityBio Inc.6.02-8.37%$6.40Bvs CGON
KODKodiak Sciences Inc97.17-0.75%$6.35Bvs CGON
SRRKScholar Rock Holding Corporation48.13-4.45%$5.87Bvs CGON
PCVXVaxcyte Inc.55.39-5.09%$8.77Bvs CGON
KRYSKrystal Biotech Inc.308.89-2.19%$9.15Bvs CGON
ADPTAdaptive Biotechnologies Corporation27.93-0.43%$4.52Bvs CGON

Related